Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections between